• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

    10/30/25 2:10:26 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAB alert in real time by email
    false 0001840563 0001840563 2025-10-26 2025-10-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): October 26, 2025

     

    PMGC Holdings Inc.
    (Exact name of registrant as specified in its charter)

     

    Nevada   001-41875   33-2382547
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I.R.S. Employer
    Identification No.)

     

    c/o 120 Newport Center Drive, Ste. 249
    Newport Beach, CA
      92660
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (888) 445-4886

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value   ELAB   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into Material Definitive Agreement

     

    On October 26, 2025, AGA Precision Systems LLC (“AGA”), a California limited liability company and a wholly owned subsidiary of PMGC Holdings Inc. (the “Company”), entered into an Asset Purchase Agreement (“Asset Purchase Agreement”) with Indarg Engineering, Inc., a California corporation (“Seller,” and, together with AGA, the “Parties”). Pursuant to the Asset Purchase Agreement, AGA purchased and assumed from Seller all of the Purchased Assets of Seller’s Business (as defined below), free and clear of any liens or other Encumbrances, subject to the terms and conditions of the Asset Purchase Agreement, and assumed the Assumed Liabilities (as defined below). Capitalized terms used in this Current Report on Form 8-K (“Form 8-K”) but not otherwise defined have the meanings set forth in the Asset Purchase Agreement.

     

    The Purchase Price for the Purchased Assets was $548,000.00, payable at Closing as follows: (a) $350,000.00 to be used to satisfy and discharge Seller’s outstanding Small Business Administration loan; (b) $28,000.00 to be paid to Seller at Closing; and (c) $170,000.00 to be paid pursuant to a two-year promissory note (“Note”) issued by AGA to the Seller, which Note will bear interest at the rate of eight percent (8%) per annum. The Note is secured by the equipment included in the Purchased Assets. At AGA’s sole option, AGA may prepay the Note in whole or in part at any time without penalty.

     

    Pursuant to the Asset Purchase Agreement, AGA shall hire Seller’s Chief Executive Officer, pursuant to an employment agreement acceptable to the Parties. The employment agreement entered into by AGA and such individual provides for, amongst other things: a base salary and signing bonus; a discretionary bonus determined by AGA in its sole discretion; and eligibility to earn incentive compensation equal to a percentage of the net income generated from any sale or transaction that such individual directly drives or originates, as determined by AGA in its reasonable discretion. Additionally, AGA shall offer employment to all employees of Seller who are eligible and qualified to work in the State of California on such terms as AGA deems appropriate.

     

    Subject to the terms and conditions set forth in the Asset Purchase Agreement, Seller agreed to non-compete provisions for a period commencing from the Closing Date to two (2) years thereafter (“Restricted Period”), which provisions apply to Seller and its Affiliates. Notwithstanding these non-compete provisions, Seller may own, directly or indirectly, solely as an investment, securities of any Person traded on any national securities exchange if Seller is not a controlling Person of, or a member of a group which controls, such Person and does not, directly or indirectly, own two percent (2%) or more of any class of securities of such Person. Seller also agreed to non-solicitation provisions applying to Seller and its Affiliates. These non-solicitation provisions do not apply to general solicitations which are not directed specifically to any employees of AGA.

     

    The Parties additionally made customary representations and warranties for transactions of this nature and agreed to other customary covenants and indemnification provisions for transactions of this nature.

     

    The transactions contemplated under the Asset Purchase Agreement were consummated on October 26, 2025.

     

    “Assumed Liabilities” means: (a) all Liabilities with respect to the Assigned Contracts, but only to the extent that such Liabilities are required to be performed after the Closing Date, were incurred in the ordinary course of business, and do not relate to any failure to perform, improper performance, warranty, or other breach, default, or violation by AGA on or prior to the Closing; (b) all Liabilities arising under that certain real property lease agreement set forth in Section 1.03(a)(ii) of the Asset Purchase Agreement, but only to the extent that such Liabilities are to be performed after the Closing Date, were incurred in the ordinary course of business, and do not relate to any failure to perform, improper performance, warranty, or other breach, default, or violation by AGA on or prior to the Closing, and excluding (c) the Excluded Liabilities.

     

    “Business” means the Seller’s business of providing high-tolerance precision machining services, including CNC machining, prototyping, and quality inspection.

     

    The foregoing descriptions of each of the Asset Purchase Agreement and the Note do not purport to be complete and are each qualified in their entirety by reference to the full text of the Securities Purchase Agreement and the form of Note, copies of which are filed as Exhibits 10.1 and 10.2, respectively, to this Form 8-K and incorporated herein by reference.

     

    1

     

    Item 2.01 Completion of Acquisition or Disposition of Assets

     

    The information set forth under Item 1.01 of this Form 8-K is incorporated herein by reference.

     

    Item 7.01 Regulation FD Disclosure

     

    On October 28, 2025, the Company issued a press release, a copy of which is furnished as Exhibit 99.1 to this Form 8-K.

     

    The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    10.1+   Asset Purchase Agreement between AGA Precision Systems LLC and Indarg Engineering, Inc. dated October 26, 2025.
    10.2   Form of Note.
    99.1   Press Release dated October 28, 2025.
    104   Cover Page Interactive Data File (formatted in Inline XBRL).

     

    +Portions of this exhibit have been redacted. The schedules, exhibits, or similar attachments have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. The Company wil furnish copies of any schedules, exhibits or similar attachments to the U.S. Securities and Exchange Commission upon request.

     

    2

      

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: October 30, 2025

     

    PMGC Holdings, Inc.  
         
    By: /s/ Graydon Bensler  
    Name: Graydon Bensler  
    Title: Chief Executive Officer,  
      Chief Financial Officer, and Director  

     

    3

     

    Get the next $ELAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & CFO Bensler Graydon was granted 3,036,437 units of Series B Preferred Stock (SEC Form 4)

    4 - PMGC Holdings Inc. (0001840563) (Issuer)

    3/28/25 9:52:32 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: New insider Bensler Graydon claimed ownership of 983,120 shares (SEC Form 3)

    3/A - PMGC Holdings Inc. (0001840563) (Issuer)

    3/28/25 9:51:28 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Braeden Lichti was granted 3,336,437 units of Series B Preferred Stock (SEC Form 4)

    4 - PMGC Holdings Inc. (0001840563) (Issuer)

    3/28/25 9:47:45 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    SEC Filings

    View All

    SEC Form 10-Q filed by PMGC Holdings Inc.

    10-Q - PMGC Holdings Inc. (0001840563) (Filer)

    11/14/25 8:41:02 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    10/30/25 3:23:41 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PMGC Holdings Inc. (0001840563) (Filer)

    10/30/25 2:10:26 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PMGC Holdings Inc. Announces AGA Precision Systems LLC's ITAR (International Traffic in Arms Regulations) Registration Approval

    NEWPORT BEACH, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:PMGC) ("PMGC" or the "Company"), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, is pleased to announce that its wholly owned subsidiary, AGA Precision Systems LLC ("AGA Precision Systems" or "AGA"), has completed International Traffic in Arms Regulations (ITAR) registration and is in compliance with ITAR. The ITAR is administered by the U.S. State Department's Directorate of Defense Trade Controls, which controls the export and import of defense articles and services. The ITAR registration further enables AGA to pursue defense and aerospace programs

    10/30/25 8:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc.'s Subsidiary, AGA Precision Systems LLC, Completes Acquisition of Indarg Engineering, Inc. Expanding Aerospace and Defense Manufacturing Platform

    Strategic Acquisition Accelerates PMGC's U.S. Manufacturing Roll-Up, Expanding Footprint Across Aerospace and Industrial Supply ChainsAcquisition Adds Profitable CNC Platform with Established Customer Relationships to drive earnings scalability and operational synergies NEWPORT BEACH, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:PMGC) ("PMGC" or the "Company"), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, today announced that its wholly owned subsidiary, AGA Precision Systems LLC ("AGA"), has acquired all operating assets of Indarg Engineering, Inc., a precision computer numerical control ("CNC") machining

    10/28/25 8:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Announces Over $711,000.00 in Sales Backlog at AGA Precision Systems LLC and Provides Corporate Update

    NEWPORT BEACH, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) ("PMGC" or the "Company" or "we"), a diversified public holding company executing a targeted roll-up strategy in U.S.-based manufacturing, today announced that its operating subsidiary AGA Precision Systems LLC ("AGA") has reported a sales backlog of approximately over $711,000 in current orders logged into its Material Requirements Planning system, Sage100. AGA has also confirmed that it is actively bidding on additional Request for Quotations totaling over $700,000 from new customers. PMGC believes AGA's current backlog and pending orders reflect robust demand, underscoring AGA's growth momentum and

    10/20/25 7:30:16 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    11/14/24 5:53:26 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/2/24 4:01:03 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Elevai Labs Inc.

    SC 13G - Elevai Labs Inc. (0001840563) (Subject)

    10/1/24 4:01:02 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Leadership Updates

    Live Leadership Updates

    View All

    PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

    NEWPORT BEACH, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (the "Company" or "PMGC," "our," or "we") (NASDAQ:ELAB), a diversified holding company, is proud to announce its annual sponsorship of TCA Venture Group's ("TCA") Orange County network for 2025. As a Southern California Network Sponsor, PMGC is actively pursuing investments and M&A opportunities to strengthen its portfolio while fostering local business growth and expanding its market presence. TCA Venture Group (formerly known as Tech Coast Angels) is one of the largest and most active angel investor networks in the United States. With a history spanning over 25 years, TCA has been instrumental in funding early-s

    2/27/25 8:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

    Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the appointment of Orian Shirihai, MD, PhD, t

    7/30/24 9:00:26 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

    NEWPORT BEACH, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ:ELAB) ("Elevai" or the "Company"), a pioneering force in medical aesthetics, announced the formation of a new Scientific Advisory Board to support the advancement of EL-22, a first-in-class engineered probiotic approach, to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. "We are honored to be forming a Scientific Advisory Board with renowned members that possess deep and complementary knowledge in metabolic diseases, obesity, weight management, muscle preservation and physical function in addition to significant experience in clinical

    6/14/24 9:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAB
    Financials

    Live finance-specific insights

    View All

    PMGC Holdings Inc. Completes Acquisition of CNC Machining Company - AGA Precision Systems LLC

    Adds $1.39 Million in Cash-Flow-Positive Revenue from a CNC Machining, Mold Manufacturing, and Specialty Metals Operation Serving the Aerospace, Defense, and Industrial Markets.Adds to PMGC's U.S. Manufacturing Revenue Through a Second Bolt-On Acquisition Under Its Roll-Up Strategy, Bringing Estimated Total Annualized Revenue to Over $2.25 Million. NEWPORT BEACH, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC" or "we"), a diversified public holding company, today announced that it has completed the acquisition of AGA Precision Systems LLC ("AGA"), a California-based CNC machining business that generated over $1.39 million in revenue in 2

    7/18/25 12:53:12 PM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PMGC Holdings Inc. Completes Acquisition of Custom IT Packaging Company Pacific Sun Packaging with Over $2,000,000 in Combined Revenue for Fiscal Years 2023 and 2024

    Serves over 300 Commercial Clients including Data Centers, Technology Manufacturers and Information Technology (IT) Service Providers.Adds cash flow positive revenue, enhances PMGC's exposure to U.S. semiconductor and artificial intelligence ("AI") infrastructure growth, and marks the launch of its strategic acquisition program targeting U.S. businesses. NEWPORT BEACH, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:ELAB) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, today announced that it has completed the acquisition of Pacific Sun Packaging Inc. ("Pacific Sun") a specialized custom IT packaging company based in San Clemente, Califor

    7/10/25 8:30:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

    Agreement adds two drug candidates to product pipeline consisting of (i) "EL-22", a clinical stage engineered probiotic expressing myostatin, and (ii) "EL-32", a preclinical engineered probiotic expressing dual myostatin & activin-A.Exclusive license covers global rights excluding South Korea.Clinical and preclinical data supports advancing EL-22, a novel investigational myostatin asset for the treatment of obesity for an investigational new drug "IND" application in 2025. EL-22 has demonstrated significant increase in body weight and restored muscle damage in preclinical mouse models, suggesting potential as a combination to glucagon-like peptide-1 "GLP-1" products to treat obesity. NEWPOR

    5/1/24 9:00:00 AM ET
    $ELAB
    Biotechnology: Pharmaceutical Preparations
    Health Care